Тофізопам (Ukrainian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Тофізопам" in Ukrainian language version.

refsWebsite

Global rank Ukrainian rank

8nih.gov

4^th place

5^th place

5doi.org

2^nd place

4^th place

3archive.org

6^th place

1books.google.com

3^rd place

11^th place

1web.archive.org

1^st place

1velapharm.com

low place

1freepatentsonline.com

5,449^th place

9,087^th place

1fda.gov

447^th place

906^th place

archive.org

Bond A, Lader M (1982). A comparison of the psychotropic profiles of tofisopam and diazepam. European Journal of Clinical Pharmacology. 22 (2): 137—42. doi:10.1007/BF00542458. PMID 6124424.
Seppälä T, Palva E, Mattila MJ, Korttila K, Shrotriya RC (1980). Tofisopam, a novel 3,4-benzodiazepine: multiple-dose effects on psychomotor skills and memory. Comparison with diazepam and interactions with ethanol. Psychopharmacology. 69 (2): 209—18. doi:10.1007/BF00427652. PMID 6109345.
Saano V (1986). Tofizopam selectively increases the action of anticonvulsants. Medical Biology. 64 (4): 201—6. PMID 3023768.

books.google.com

Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. с. 1041. ISBN 978-3-88763-075-1.

doi.org

Bond A, Lader M (1982). A comparison of the psychotropic profiles of tofisopam and diazepam. European Journal of Clinical Pharmacology. 22 (2): 137—42. doi:10.1007/BF00542458. PMID 6124424.
Seppälä T, Palva E, Mattila MJ, Korttila K, Shrotriya RC (1980). Tofisopam, a novel 3,4-benzodiazepine: multiple-dose effects on psychomotor skills and memory. Comparison with diazepam and interactions with ethanol. Psychopharmacology. 69 (2): 209—18. doi:10.1007/BF00427652. PMID 6109345.
Leventer SM, Raudibaugh K, Frissora CL, Kassem N, Keogh JC, Phillips J, Mangel AW (January 2008). Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 27 (2): 197—206. doi:10.1111/j.1365-2036.2007.03566.x. PMID 17973974.
Drabant S, Tóth M, Bereczki A, Bajnógel J, Tömlö J, Klebovich I (July 2006). Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. European Journal of Clinical Pharmacology. 62 (7): 587—8. doi:10.1007/s00228-006-0160-9. PMID 16791582.
Tóth M, Drabant S, Varga B, Végso G, Cseh A, Szentpéteri I, Klebovich I (January 2008). Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam. European Journal of Clinical Pharmacology. 64 (1): 93—4. doi:10.1007/s00228-007-0397-y. PMID 17989974.

fda.gov

Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. FDA. 26 травня 2021.

freepatentsonline.com

Nielsen EB, Kehler J, Nielsen J, Brøsen P. Use of Tofisopam as a PDE10A inhibitor.

nih.gov

pubmed.ncbi.nlm.nih.gov

Bond A, Lader M (1982). A comparison of the psychotropic profiles of tofisopam and diazepam. European Journal of Clinical Pharmacology. 22 (2): 137—42. doi:10.1007/BF00542458. PMID 6124424.
Seppälä T, Palva E, Mattila MJ, Korttila K, Shrotriya RC (1980). Tofisopam, a novel 3,4-benzodiazepine: multiple-dose effects on psychomotor skills and memory. Comparison with diazepam and interactions with ethanol. Psychopharmacology. 69 (2): 209—18. doi:10.1007/BF00427652. PMID 6109345.
Saano V (1986). Tofizopam selectively increases the action of anticonvulsants. Medical Biology. 64 (4): 201—6. PMID 3023768.
Petócz L (March 1993). [Pharmacologic effects of tofizopam (Grandaxin)]. Acta Pharmaceutica Hungarica. 63 (2): 79—82. PMID 8100112.
Leventer SM, Raudibaugh K, Frissora CL, Kassem N, Keogh JC, Phillips J, Mangel AW (January 2008). Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 27 (2): 197—206. doi:10.1111/j.1365-2036.2007.03566.x. PMID 17973974.
Tóth M, Bajnógel J, Egyed A, Drabant S, Tömlo J, Klebovich I (2005). [Effect of tofisopam on CYP3A4 enzyme activity on human recombinant 3A4 supersome]. Acta Pharmaceutica Hungarica. 75 (4): 195—8. PMID 16711396.
Drabant S, Tóth M, Bereczki A, Bajnógel J, Tömlö J, Klebovich I (July 2006). Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. European Journal of Clinical Pharmacology. 62 (7): 587—8. doi:10.1007/s00228-006-0160-9. PMID 16791582.
Tóth M, Drabant S, Varga B, Végso G, Cseh A, Szentpéteri I, Klebovich I (January 2008). Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam. European Journal of Clinical Pharmacology. 64 (1): 93—4. doi:10.1007/s00228-007-0397-y. PMID 17989974.

velapharm.com

Vela Pharmaceuticals (2005). Vela Announces Positive Phase 2 Results for Dextofisopam in Treating Irritable Bowel Syndrome - IBS: Results Show Effects of Dextofisopam Both in Women and in Men. VelaPharm - News. Архів оригіналу за 2 травня 2005. Процитовано 21 лютого 2006. [Архівовано 2005-05-02 у Wayback Machine.]

web.archive.org

Vela Pharmaceuticals (2005). Vela Announces Positive Phase 2 Results for Dextofisopam in Treating Irritable Bowel Syndrome - IBS: Results Show Effects of Dextofisopam Both in Women and in Men. VelaPharm - News. Архів оригіналу за 2 травня 2005. Процитовано 21 лютого 2006. [Архівовано 2005-05-02 у Wayback Machine.]